


Pharmaceuticals in the environment – an environmental hazard?


Leif Kronberg

Åbo Akademi University, Laboratory of Organic Chemistry

Public interest in the topic



Sources and pathways of pharmaceuticals to the aquatic environment



Source: Heberer, *Toxicol Lett*, 2002 (131), 5-17

Why should we study pharmaceuticals in the environment?

- The compounds are continuously discharged to the environment from sewage treatment plants
⇒ THE COMPOUNDS ARE PSEUDOPERSISTENT
- The compounds are biologically active and there are thousands of different substances (the parent compounds and the metabolites)
⇒ A PHARMACEUTICAL COCKTAIL
- In recent studies, already concentrations of < 10 ng/L of a certain pharmaceutical have been showed to caused behavioral disturbances in aquatic organisms.
- It is known that additive effects of mixtures of pharmaceuticals have to be considered when risk assessments are made
⇒ RISK FOR THE AQUATIC ENVIRONMENT IS EVIDENT

HDR 2008

5

Factors (determinants) affecting the occurrence and the impact of pharmaceuticals in the environment

- Consumption
 - High/low
- Metabolism
 - Phase 1 ⇒ inactivation
 - Conjugation of parent compound ⇒ may not be important
- Sewage treatment
 - Biodegradation/biotransformation/deconjugation
 - Sorption
- Surface water (aquatic environment)
 - Dilution
 - Phototransformation
 - Reactions at surfaces of particles? (Biodegradation/biotransformation)
 - Sorption & sedimentation
- Biota
 - Uptake
 - Metabolism
 - Distribution
 - Excretion

HDR 2008

6

Waste water discharges

- The cmpds not removed to 100% in the STP are found in the effluent and consequently discharged to the aquatic environment
 - the concentrations in the effluent are usually much lower than in the influent
 - the concentration profile is different from that in the influent
 - the cmpds are further diluted in the recipient waters

HDR 2008

7

Fate in the aquatic environment

- A very complex issue – the environmental conditions play an important role and these vary from location to location
 - Cmpds that absorb light at 290 – 800 nm may undergo **phototransformation**
 - environmental fate of transformation products?
 - Sorption and sedimentation
 - not a degradation process but may offer surfaces for **catalytic transformations**?
 - The impact of humic substances (NOM)
 - act as a "sink" for the compounds?
 - Biotransformation/biodegradation
 - it is not likely that compounds not undergoing biotransformation in the sewage plant would undergo transformation in the aquatic environment
 - A steady discharge of "new" compounds
 - pseudopersistence!

HDR 2008

8

Risk for the Aquatic Environment (1)

- Highest risk of contamination: lakes, rivers and the ground water
- We have to consider the risk of the:
 - parent compound
 - the mixture of compounds
 - the transformation products
 - some transformation products may be of higher risk than the parent compounds

HDR 2008

9

Risk for the Aquatic Environment (2)

- Established risks
 - Ethinyl estradiol cause infertility in fish at concentration < 5 ng/L
 - A mixture of estrogenic compounds is a much more potent endocrine disruptor than the single compounds.
- Assumed effects
 - Spreading of drug resistant pathogens
 - Bioconcentration and biomagnification
 - Risks in conjunction with the sediments

HDR 2008

10

Human risk

- Mainly through drinking water (a risk?)
- Or through disturbance of the ecological integrity

HDR 2008

11


Disruption of Environmental Integrity

- Decline in the vulture population in India due to veterinary use of diclofenac (Oaks et al. *Nature*, 2004, 427, 630)



Figure 1 Oriental white-backed vultures, *Gyps bengalensis*—alive, feeding on the carcass of a buffalo, and dead.

NATURE [VOL. 427 (1) 2 FEBRUARY 2004] www.nature.com/nature



HDR 2008

12


Pharmaceuticals in waste water and in the environment in Finland

Some results of our studies
(Our = Niina Vieno, Tuula Tuhkanen and Leif Kronberg)

HDR 2008

13

Some of the Studied Pharmaceuticals



HDR 2008

14

CONSUMPTION OF STUDIED PHARMACEUTICALS IN FINLAND


SUBSTANCE	USE (kg/year)	USE (mg/inh/year)*
Ibuprofen	70 200	13 500
Naproxen	6 700	1 300
Ketoprofen	1 400	270
Diclofenac	965	190
Bezafibrate	510	100

* Population of Finland= 5 212 000

HDR 2008

15

Concentrations in the Influent of WWTPs



The same concentration profile as the consumption profile

HDR 2008

16

Theoretical Calculation of the Concentration of Pharmaceuticals in Waste Water Influent


$$C_{calc} = \frac{A \times P \times e\% \times 10}{365 \times Q}$$

- C_{calc} = theoretically calculated concentration of a pharmaceutical in STP influent ($\mu\text{g l}^{-1}$)
- A = the amount of a pharmaceutical used per year per capita (in grams per inhabitant per year)
- P = the number of inhabitants serviced by the STP
- $e\%$ = the amount of a pharmaceuticals excreted unchanged by humans (in %)
- Q_{inf} = the influent flow (m^3d^{-1})

HDR 2008

17

Comparison of Calculated and Measured Concentrations



- CIP = Ciprofloxacin
- NOR = Norfloxacin
- OFL = Ofloxacin
- CBZ = Carbamazepine
- ACE = Acetololol
- ATE = Atenolol
- MET = Metoprolol
- SOT = Sotalol

HDR 2008

18

Vice versa: The Consumption Can be Determined from the Measured Influent Concentrations

Example: ibuprofen in Helsinki

$c(\text{ibuprofen})$ in STP influent = $12.2 \mu\text{g/l}$

influent flow = $206\,000 \text{ m}^3/\text{d}$

→ 2.5 kg of ibuprofen per day to the STP

About 90% metabolized in humans

→ Use of ibuprofen in Helsinki per day is about 25 kg .

→ Which makes about $12\,500 \text{ mg}$ of ibuprofen/inh/year.


→ National Agency of Medicine reports: $13\,500 \text{ mg IBU/inh/year}$

This example shows that our analytical method is reliable

HDR 2008

19

Concentrations in the Effluent of WWTPs



Example: * ibuprofen load to the environment in Helsinki = 20 kg/yr

* Load of all the studied pharmaceuticals = 200 kg/yr

HDR 2008

20

Summary of Elimination Rates in WWTPs


- (I) Efficient elimination (>80%): ciprofloxacin, norfloxacin, ofloxacin, ibuprofen, ketoprofen and naproxen
- (II) Moderate elimination (40–80%): acebutolol, atenolol, sotalol and bezafibrate
- (II) Poor elimination (<40%): diclofenac and metoprolol
- (IV) No elimination: carbamazepine

HDR 2008

21

Concentration of Pharmaceuticals in River Water (River Aura)


Samples collected upstream (-0.5 km), at the discharge point (0 km) and downstream (1, 5, 8, 14, 23 and 32 km) from a waste water treatment plant



HDR 2008

22

Concentration of Pharmaceuticals in River Water (River Vantaa)




The compounds are abundant in the River Vantaa!

HDR 2008

23

RESULTS - Drinking water treatment (4)

The ozonation step is by-passed (no ozonation)



HDR 2008

24


Further work

- The environmental fate of pharmaceuticals
 - How stable are the compounds
 - Bioavailability?
 - Phototransformation
 - The significance of transformation products

HDR 2008

25

Phototransformation of diclofenac




Some chlorinated dibenzofuranes are known to be very toxic, but do we know anything about the toxicity of chlorinated carbazoles?

HDR 2008

26

Bioavailability

- We have found diclofenac and naproxen metabolites in bile of fish exposed to the compounds.



HDR 2008

27

Conclusions

- The pharmaceuticals are not fully eliminated in WWTPs and consequently they are discharged to the aquatic environment
- They are detected in river waters downstream WWTPs at concentrations up to 100 ng/L
- The environmental impact and fate are largely unknown, but recent studies have shown that some of the compounds may have deleterious effects on certain organisms
- It is obvious that we have to find means to minimize the discharge of pharmaceuticals to the environment

HDR 2008

28

Coworkers

- Dr. Niina Vieno,
- Prof. Tuula Tuhkanen
- Prof. Aimo Oikari
- Doctorals students Jesper Svanfelt,
Jenny-Maria Kallio, Jussi Kosonen,
Marja Lahti

Thank you for your attention
